Finch Therapeutics Group (NASDAQ:FNCH – Get Free Report) and Vaxcyte (NASDAQ:PCVX – Get Free Report) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, risk, analyst recommendations, profitability, valuation and dividends.
Analyst Recommendations
This is a summary of recent recommendations and price targets for Finch Therapeutics Group and Vaxcyte, as provided by MarketBeat.com.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Finch Therapeutics Group | 0 | 0 | 0 | 0 | N/A |
Vaxcyte | 0 | 0 | 4 | 0 | 3.00 |
Vaxcyte has a consensus price target of $78.50, suggesting a potential upside of 2.94%. Given Vaxcyte’s higher possible upside, analysts plainly believe Vaxcyte is more favorable than Finch Therapeutics Group.
Volatility & Risk
Insider and Institutional Ownership
21.8% of Finch Therapeutics Group shares are owned by institutional investors. Comparatively, 96.8% of Vaxcyte shares are owned by institutional investors. 44.9% of Finch Therapeutics Group shares are owned by insiders. Comparatively, 3.1% of Vaxcyte shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Profitability
This table compares Finch Therapeutics Group and Vaxcyte’s net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Finch Therapeutics Group | N/A | -68.11% | -28.10% |
Vaxcyte | N/A | -28.83% | -26.89% |
Earnings & Valuation
This table compares Finch Therapeutics Group and Vaxcyte’s revenue, earnings per share and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Finch Therapeutics Group | $110,000.00 | 18.73 | -$74.75 million | ($10.14) | -0.13 |
Vaxcyte | N/A | N/A | -$402.27 million | ($4.28) | -17.82 |
Finch Therapeutics Group has higher revenue and earnings than Vaxcyte. Vaxcyte is trading at a lower price-to-earnings ratio than Finch Therapeutics Group, indicating that it is currently the more affordable of the two stocks.
Summary
Vaxcyte beats Finch Therapeutics Group on 7 of the 11 factors compared between the two stocks.
About Finch Therapeutics Group
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts.
About Vaxcyte
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
Receive News & Ratings for Finch Therapeutics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Finch Therapeutics Group and related companies with MarketBeat.com's FREE daily email newsletter.